The Uromigos Live & Unplugged
Exclusive coverage of The Uromigos’ first live, in-person event, being held in Nashville, Tennessee, September 30 through October 1.
Advertisement
Event Coverage
The Uromigos: Live & Unplugged event incorporated presentations and discussions in the field of urologic malignancies.
Cancer patient Michael Whitley explains how The Uromigos help him understand new prostate cancer treatments and research.
Matthew Tucker, MD from Grandview Cancer Center talks about why he enjoys The Uromigos and what his favorite episodes are.
Chandler Park, MD from University of Louisville Hospital talks about why he recommends The Uromigos podcast.
Petros Grivas, MD, PhD, Director of UW Medicine's GU Cancers Program, talks about the efficacy of sacituzumab govitecan.
Shilpa Gupta, MD discusses maintenance therapy for bladder cancer, including the current standard of care and ongoing trials.
Thomas Powles, MBBS, MRCP, MD gives an overview of highlights from The Uromigos: Live & Unplugged bladder cancer session.
Matthew Galsky, MD gives insight on adjuvant nivolumab trials, including use in unselected patients and overall survival.
Kala Sridhar talks about bladder-sparing treatments for urothelial carcinoma and how patient populations are shifting.
Jonathan Rosenberg, MD talks about the development of enfortumab vedotin, including monotherapy info and combination data.
Christopher Sweeney talks about prostate cancer trials investigating the use of ADT + docetaxel or cabazitaxel.
Christopher Sweeney, MBBS, gives us his insight on the future of prostate cancer care and research in the year 2027.
Nick James, MBBS, PhD, FRCP, FRCR, discusses his outlook on the future of prostate cancer treatment in the year 2027.
Daniel George, MD, Duke University School of Medicine, gives us insight on what to expect from the future of mHSPC treatment.
Neeraj Agarwal, MD, Professor of Medicine, gives his outlook on the future of cancer care and treatment for mHSPC in 2027.
Sumanta Pal, MD, FASCO, from City of Hope talks about new drugs and the ongoing TiNivo-2 trial for renal cell carcinoma.
David McDermott, MD talks about monotherapy and combination therapy for RCC and future advances in RCC treatment.
Rana McKay, MD, GU Medical Oncologist from UCSD, gives her outlook on the future of prostate cancer care in the year 2025.
Michael Morris, MD, of Memorial Sloan Kettering Cancer Center gives his predictions for the future of mHSPC treatment.
Featuring panelists Neeraj Agarwal, MD, Daniel George, MD, Nick James, MBBS, PhD, FRCP, FRCR, Rana McKay, MD, and more.
The bladder cancer buzzer round from The Uromigos: Live & Unplugged.
Tian Zhang gives a quick recap of the Frontline Therapy in RCC panel from The Uromigos Live & Unplugged.
Axel Bex gives a quick recap of the renal panel on adjuvant therapy in RCC from The Uromigos Live & Unplugged.
The Uromigos and a panel of RCC experts discuss data on perioperative therapy in RCC, and the next adjuvant therapy trials.
A panel of RCC experts discuss frontline therapy for kidney cancer, as well as where they see it headed in the next 5 years.
Join us for The Uromigos Live & Unplugged in Nashville, Tennessee, September 30 through October 1, at the Thompson Nashville.
Advertisement
